Article
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.
ESMO open - 1 Jun 2026
Im S-A, Kalinsky K, Jhaveri K L, Loibl S, Turner N, Saura C, Schmid P, Loi S, Hamilton E, Karadurmus N, Wang S, Awan A A, Ciruelos E M, Chung C-F, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Juric D
Abstract excerpt
BACKGROUND: INAVO120 (NCT04191499) demonstrated significantly improved progression-free/overall survival with inavolisib plus palbociclib-fulvestrant versus placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. We provide comprehensive analyses of key selected adverse events and their management. MATERIALS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.